Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
TREATMENT OF INFLUENZA — Three neuraminidase inhibitors (oral oseltamivir, IV peramivir, and inhaled zanamivir) and the oral cap-dependent endonuclease inhibitor baloxavir marboxil are available in the US...
- Marstacimab (Hympavzi) for Hemophilia A and B
- In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive
- Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)
- Isatuximab (Sarclisa) for Multiple Myeloma (online only)
- Ribociclib (Kisqali) for Early Breast Cancer (online only)
- Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)
RELEASE
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide (Byetta, Bydureon BCise), liraglutide (Saxenda, Victoza), and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative fasting.
MECHANISM — GLP-1 receptor agonists and tirzepatide delay gastric emptying and commonly cause nausea, vomiting, and abdominal distension, but these adverse effects generally decrease with long-term use. Delayed gastric emptying can increase the risk of …